Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
about
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Genomic profiling of small-cell lung cancer: the era of targeted therapiesPreclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.EGFR-TKI resistance in NSCLC patients: mechanisms and strategiesAlteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancerPemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway.Inhibition of Human Lung Cancer Cell Proliferation and Survival by Post-Exercise Serum Is Associated with the Inhibition of Akt, mTOR, p70 S6K, and Erk1/2.Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Targeting the raft-associated Akt signaling in hepatocellular carcinoma.Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progressionMig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathwayMer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsEffects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell linesTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.Translational research in endocrine surgery.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatmentTumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53.Allosteric therapies for lung cancer.Pluripotency transcription factors in lung cancer-a review.miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.Fisetin, a dietary bioflavonoid, reverses acquired Cisplatin-resistance of lung adenocarcinoma cells through MAPK/Survivin/Caspase pathway.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by 'Iturin A' a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium.Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation.miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.Research progress on the impact of radiation on TKI resistance mechanisms in NSCLC
P2860
Q26741814-A9BAA69F-F862-49A5-BCF2-183F60E34C69Q26826915-63544683-9C8D-40E0-A0A2-7DAD17E0E721Q26863474-38A12546-DE9D-44EB-ABD0-7D8DB3CA32F9Q27853391-4A4496B9-AC75-4D7B-98F5-047019AADE77Q28394310-F6C849AB-5BA8-41BF-9F06-73B334A51144Q28541175-E554ED15-D89E-49C6-ADC6-3FAA6292659AQ33646091-D09379B4-09A5-4886-BF29-430198F24757Q33737286-3706169E-EFEE-4C05-B9CF-75E530DF37F0Q33779061-76A3A9AC-08AB-44BB-8C75-3658C467E24BQ33779591-00A4CB71-48BB-4B9D-BE8D-5686A0A2E08DQ33946123-EB2C271D-8F4A-4C7D-8CAA-32FA84F8D49EQ34134584-ED5E6C65-D6D8-4455-A801-51FBE972DAD5Q34177619-CA40F031-7356-4841-A82F-771BBDA8D744Q34294188-F4BF9B03-CDCA-429C-85D9-FCA77EA2E695Q34501686-8BB65CAC-0856-4DBF-8972-08487F566B18Q34987170-3E3D1C05-AB66-481E-A33A-B3B2C40D9F09Q35578544-CB875251-E3C6-4C2A-9444-A61DD24EEEF6Q35832327-37DD39C8-DD4F-4FC5-A8BE-681CE645C9C1Q35987305-6F1C3B64-10E5-4287-9C7E-CBE8E0865D72Q36036046-F473FD3B-5FBE-4E0E-9BBD-4F2DA185DA3AQ36999705-D88E0878-FBC3-40A1-B16D-6A95C1EC2A79Q37317400-4C27AA08-FE6C-432C-81F1-DEDAA041CF58Q37571930-146F5A8E-FF5B-4E2E-A8E6-F1B14D83F402Q38135137-4158A15B-5B6A-416E-9BD2-73B8B84BFFD4Q38175044-42F306C1-E495-416F-85A9-F0811670A112Q38262500-34D4CB8C-A530-4FBE-80B6-5799BE95C0F7Q38390044-08DDDE66-5481-4CB8-B62B-59E947C4A5EAQ38451785-A4BC2E9C-1EAB-42F9-BA34-784D51D4F09DQ38465098-2E53C513-CFD6-4971-AA0C-EF7B91B2463CQ38637870-C850C7AB-0CA3-4C74-AB0C-82D22A614866Q38727344-9148A7AF-8F80-40E6-8F82-9833297262C8Q38728165-FFA6C427-2FE4-4A8A-8D52-198EAE920905Q38982951-1FAB638E-2284-44EE-B9D9-6B4AA9972CF1Q38988072-1CCCEEC1-15E1-4F14-B2EA-4471C035C3B5Q41876233-E4E89569-CB79-4793-942A-47AA87B98EA4Q47146662-7EE8E23C-DDC6-418A-B3D1-E4CF368963F6Q47155959-172C0C14-BA34-497C-852F-6A60D4C890A0Q51452297-79462A3C-C9E0-4FE2-BFD4-75E4A80755E1Q53413935-ECBC2410-661A-4039-AD96-BE0F512EA798Q58594883-F955E748-16B5-443B-87CE-ACF9409ACE6B
P2860
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Preclinical rationale for PI3K ...... nt non-small-cell lung cancer.
@en
type
label
Preclinical rationale for PI3K ...... nt non-small-cell lung cancer.
@en
prefLabel
Preclinical rationale for PI3K ...... nt non-small-cell lung cancer.
@en
P1433
P1476
Preclinical rationale for PI3K ...... nt non-small-cell lung cancer.
@en
P2093
Antoinette Wozniak
Shirish M Gadgeel
P304
P356
10.1016/J.CLLC.2012.12.001
P407
P577
2013-01-16T00:00:00Z